Kim Hongsik, Choi Song-Yi, Heo Tae-Young, Kim Kyeong-Rok, Lee Jisun, Yoo Min Young, Lee Taek-Gu, Han Joung-Ho
Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, South Korea.
Department of Pathology, Chungnam National University College of Medicine, Daejeon 35015, South Korea.
World J Clin Cases. 2024 Feb 16;12(5):931-941. doi: 10.12998/wjcc.v12.i5.931.
There are limited data on the use of glucose transport protein 1 (GLUT-1) expression as a biomarker for predicting lymph node metastasis in patients with colorectal cancer. GLUT-1 and GLUT-3, hexokinase (HK)-II, and hypoxia-induced factor (HIF)-1 expressions may be useful biomarkers for detecting primary tumors and lymph node metastasis when combined with fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT).
To evaluate GLUT-1, GLUT-3, HK-II, and HIF-1 expressions as biomarkers for detecting primary tumors and lymph node metastasis with 18F-FDG-PET/CT.
This retrospective study included 169 patients with colorectal cancer who underwent colectomy and preoperative 18F-FDG-PET/CT at Chungbuk National University Hospital between January 2009 and May 2012. Two tissue cores from the central and peripheral areas of the tumors were obtained and were examined by a dedicated pathologist, and the expressions of GLUT-1, GLUT-3, HK-II, and HIF-1 were determined using immunohistochemical staining. We analyzed the correlations among their expressions, various clinicopathological factors, and the maximum standardized uptake value (SUVmax) of PET/CT.
GLUT-1 was found at the center or periphery of the tumors in 109 (64.5%) of the 169 patients. GLUT-1 positivity was significantly correlated with the SUVmax of the primary tumor and lymph nodes, regardless of the biopsy site (tumor center, < 0.001 and = 0.012; tumor periphery, = 0.030 and = 0.010, respectively). GLUT-1 positivity and negativity were associated with higher and lower sensitivities of PET/CT, respectively, for the detection of lymph node metastasis, regardless of the biopsy site. GLUT3, HK-II, and HIF-1 expressions were not significantly correlated with the SUVmax of the primary tumor and lymph nodes.
GLUT-1 expression was significantly correlated with the SUVmax of 18F-FDG-PET/CT for primary tumors and lymph nodes. Clinicians should consider GLUT-1 expression in preoperative endoscopic biopsy in interpreting PET/CT findings.
关于使用葡萄糖转运蛋白1（GLUT-1）表达作为预测结直肠癌患者淋巴结转移生物标志物的数据有限。当与正电子发射断层扫描/计算机断层扫描（PET/CT）上的氟脱氧葡萄糖（FDG）摄取相结合时，GLUT-1和GLUT-3、己糖激酶（HK）-II以及缺氧诱导因子（HIF）-1的表达可能是检测原发性肿瘤和淋巴结转移的有用生物标志物。
评估GLUT-1、GLUT-3、HK-II和HIF-1的表达作为通过18F-FDG-PET/CT检测原发性肿瘤和淋巴结转移的生物标志物。
这项回顾性研究纳入了2009年1月至2012年5月期间在忠北国立大学医院接受结肠切除术和术前18F-FDG-PET/CT检查的169例结直肠癌患者。从肿瘤的中央和周边区域获取两个组织芯，由专业病理学家进行检查，并使用免疫组织化学染色确定GLUT-1、GLUT-3、HK-II和HIF-1的表达。我们分析了它们的表达、各种临床病理因素以及PET/CT的最大标准化摄取值（SUVmax）之间的相关性。
在169例患者中的109例（64.5%）肿瘤中央或周边发现了GLUT-1。无论活检部位如何，GLUT-1阳性与原发性肿瘤和淋巴结的SUVmax均显著相关（肿瘤中央，<0.001和=0.012；肿瘤周边，=0.030和=0.010）。无论活检部位如何，GLUT-1阳性和阴性分别与PET/CT检测淋巴结转移的较高和较低敏感性相关。GLUT3、HK-II和HIF-1的表达与原发性肿瘤和淋巴结的SUVmax无显著相关性。
GLUT-1表达与原发性肿瘤和淋巴结的18F-FDG-PET/CT的SUVmax显著相关。临床医生在术前内镜活检中解读PET/CT结果时应考虑GLUT-1表达。
